CRNX insider buying and SEC filings, explained
Crinetics Pharmaceuticals, Inc. · CIK 1658247
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$6.5M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 2, 2026 | Planned (10b5-1) | Coelho Rogerio Vivaldi (Director) sold 3,000 shares at $40.00 ($120K), marked as a 10b5-1 plan trade. Holdings down 13% to 19,225 shares. | SEC filing Filed Jul 7, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Stephanie Okey (Director) sold 6,900 shares at about $35.67 ($246K), marked as a 10b5-1 plan trade. Holdings down 52% to 6,400 shares. | SEC filing Filed Jun 18, 2026 |
| Apr 8, 2026 | Planned (10b5-1) | Jeff E. Knight (Chief Dev. & Operating Officer) sold 85,163 shares at about $40.10 ($3.4M), marked as a 10b5-1 plan trade. Holdings down 45% to 105,289 shares. | SEC filing Filed Apr 10, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Jeff E. Knight (President / COO) sold 9,911 shares at about $37.37 ($370K), marked as a 10b5-1 plan trade. Holdings down 8% to 112,018 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Stephen F. Betz (Chief Scientific Officer) sold 10,612 shares at about $37.37 ($397K), marked as a 10b5-1 plan trade. Holdings down 7% to 137,101 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Richard Scott Struthers (CEO and Director) sold 21,981 shares at about $37.37 ($822K), marked as a 10b5-1 plan trade. Holdings down 5% to 404,778 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 12, 2026 | Planned (10b5-1) | Coelho Rogerio Vivaldi (Director) sold 5,000 shares at about $36.15 ($181K), marked as a 10b5-1 plan trade. Holdings down 23% to 16,300 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Stephanie Okey (Director) sold 3,000 shares at $39.67 ($119K), marked as a 10b5-1 plan trade. Holdings down 18% to 13,300 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Tobin Schilke (CFO) sold 6,713 shares at about $39.67 ($266K), marked as a 10b5-1 plan trade. Holdings down 8% to 78,121 shares. | SEC filing Filed Mar 4, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Isabel Kalofonos (Chief Commercial Officer) sold 2,500 shares at $55.00 ($138K), marked as a 10b5-1 plan trade. Holdings down 75% to 834 shares. | SEC filing Filed Jan 7, 2026 |
| Dec 1, 2025 | Planned (10b5-1) | Dana Pizzuti (Chief Med and Dev Officer) sold 5,000 shares at about $45.02 ($225K), marked as a 10b5-1 plan trade. Holdings down 7% to 66,837 shares. | SEC filing Filed Dec 3, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Dana Pizzuti (Chief Med and Dev Officer) sold 5,000 shares at about $42.66 ($213K), marked as a 10b5-1 plan trade. Holdings down 7% to 66,270 shares. | SEC filing Filed Nov 5, 2025 |
32 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CRNX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.